FibroGen, Inc. (FGEN)

FibroGen Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-240.46	-284.23	-293.65	-290.02	-189.29	-76.97
Depreciation & Amortization	7.79	9.93	10.6	14.81	22.05	21.45
Share-Based Compensation	43.42	50.77	65.6	71.16	72.72	66.27
Other Operating Activities	-83.46	-91.49	71.52	121.82	176.13	-89.46
Operating Cash Flow	-272.72	-315.02	-145.93	-82.23	81.6	-78.71
Capital Expenditures	-1.96	-2.52	-3.74	-5.19	-3.99	-5.76
Acquisitions	0.66	0.66	-35	-25	-2.83	0
Change in Investments	102.75	155.52	127.85	-396.79	459.31	125.77
Investing Cash Flow	101.45	153.66	89.12	-426.97	452.49	120.02
Share Issuance / Repurchase	20.48	52.14	4.18	12.7	37.83	20.78
Debt Issued / Paid	71.01	70.85	47.76	-5.89	-13.02	-12.33
Other Financing Activities	-0.39	-0.24	-5.17	-7.37	-11.46	-12.75
Financing Cash Flow	91.1	122.75	46.78	-0.56	13.34	-4.3
Exchange Rate Effect	-2.65	-3.4	-5.48	2.6	4.7	-0.01
Net Cash Flow	-82.82	-42.01	-15.52	-507.17	552.13	37.01
Free Cash Flow	-274.68	-317.54	-149.67	-87.42	77.61	-84.46
Free Cash Flow Margin	-163.99%	-214.91%	-106.35%	-37.15%	44.02%	-32.92%
Free Cash Flow Per Share	-2.77	-3.26	-1.60	-0.95	0.86	-0.97

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).